Polyrizon's Groundbreaking Safety Study Results
Polyrizon Ltd. (NASDAQ: PLRZ), a pioneering biotech company dedicated to creating innovative intranasal hydrogels, is excited to announce the promising results of a preliminary safety study for its PL-14 Allergy Blocker. This formulation has the potential to significantly enhance the management of allergies, representing a substantial step forward in its clinical development.
Overview of the Safety Study
The study, which utilized the advanced MucilAir™ model on fully differentiated human nasal tissue, showcased impressive local tolerability. This is essential for understanding how the formulation interacts with nasal tissues, ensuring that future applications are not only effective but also safe for users.
Study Design and Key Findings
Designed to evaluate local tolerance following a four-hour application of the PL-14 nasal gel spray, the study focused on its ability to act as a protective barrier against allergens. The PL-14 Allergy Blocker is engineered to maintain its effectiveness in the nasal cavity for about four hours after use.
Critical safety indicators such as tissue integrity, cytotoxicity, cilia beating frequency, mucociliary clearance, and inflammatory response were meticulously assessed. The results indicated that tissue viability remained consistent with baseline levels, with no indications of inflammation or functional impairment in nasal epithelial activity.
The Vision for PL-14 Allergy Blocker
“These results mark a pivotal milestone in affirming the local safety of our PL-14 formulation,” stated Tomer Izraeli, CEO of Polyrizon. “Our aspiration is to develop a drug-free, well-tolerated nasal spray that establishes a robust protective barrier against airborne allergens daily.” This vision aligns with Polyrizon's overarching goal to enhance allergy management through innovative technology.
Advancing Towards Clinical Trials
The promising study outcomes are vital for Polyrizon’s broader verification and validation (V&V) program. This program is essential as the company prepares for an FDA pre-submission meeting, which will contribute to its regulatory strategy and future clinical trial applications.
Polyrizon is enthusiastic about the trajectory these findings create, paving the path for upcoming clinical trials in both the United States and Europe, anticipated to commence in the near future.
About Polyrizon Ltd.
Polyrizon is committed to transforming allergy management with its innovative nasal spray formulations. The company is focused on developing medical device hydrogels that not only form a protective barrier in the nasal cavity but also serve to reduce exposure to pathogens and allergens. Their proprietary Capture and Contain (C&C) hydrogel technology exemplifies this vision, potentially functioning as a ‘biological mask’ to shield nasal epithelial tissues from harmful agents. Moreover, Polyrizon is expanding its capabilities in the area of targeted intranasal delivery of drugs through its Trap and Target (T&T) technology.
Contact Information
For further inquiries, reach out to:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
Frequently Asked Questions
What is the significance of Polyrizon’s safety study results?
The safety study results validate the local tolerability of the PL-14 Allergy Blocker, allowing the company to proceed with its clinical development plans.
How does the PL-14 Allergy Blocker work?
The PL-14 formulation acts as a physical barrier against airborne allergens, helping to protect nasal tissues from irritation and allergic reactions.
What are the next steps for Polyrizon after the study?
Polyrizon plans to advance towards clinical trials, with an upcoming FDA pre-submission meeting being a crucial part of their regulatory strategy.
What technology does Polyrizon utilize in its products?
Polyrizon uses proprietary hydrogel technology designed to create a protective shield in the nasal cavity, reducing exposure to viruses and allergens.
Is the PL-14 Allergy Blocker drug-free?
Yes, the PL-14 Allergy Blocker is designed to be drug-free, offering a well-tolerated option for daily allergy protection.
